QIAGEN N.V. reported third-quarter 2026 net sales of $548 million, a 3% increase from the prior year period and consistent with constant exchange rate growth. Adjusted diluted earnings per share rose to $0.65, up from $0.61 in Q3 2025, while adjusted operating income margin expanded to 30.4%. The company suspended its full-year financial outlook due to a pending acquisition transaction. On October 21, 2026, EQT Private Equity announced an agreement for Crown NL Bidco B.V. to make a voluntary all-cash public takeover offer for all outstanding QIAGEN shares at €46.50 per share, with closing expected in mid-2027. The company operates in the life sciences and molecular diagnostics industry.
